Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.39 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28803391 | 0.84 | ALOX15 (0.50) | ALOX15ALDH1A1CYP2C9HSD17B10TYR | |
| SCHEMBL20993111 | 0.78 | KDM4E (0.32) | ALOX15ALDH1A1SMN1; SMN2CYP1A2MAPT | |
| SCHEMBL17693529 | 0.78 | HSD17B10 (0.56) | ALOX15ALDH1A1CYP2C9HSD17B10TYR | |
| SCHEMBL25724937 | 0.78 | ALDH1A1 (0.45) | ALOX15ALDH1A1CYP2C9HSD17B10TYR | |
| SCHEMBL1042697 | 0.77 | SMN1; SMN2 (0.46) | ALOX15ALDH1A1CYP2C9HSD17B10TYR | |
| SCHEMBL8415616 | 0.77 | ALOX15 (0.62) | ALOX15ALDH1A1CYP2C9HSD17B10TYR | |
| SCHEMBL1042661 | 0.77 | GABRA1 (0.34) | ALOX15ALDH1A1CYP2C9SMN1; SMN2CYP1A2 | |
| SCHEMBL25696416 | 0.77 | ALDH1A1 (0.43) | ALOX15ALDH1A1CYP2C9HSD17B10TYR | |
| SCHEMBL758610 | 0.77 | HSD17B10 (0.50) | ALOX15HSD17B10CYP3A4CHRM1MAOA | |
| SCHEMBL26058906 | 0.73 | ESR1 (0.38) | ALOX15ALDH1A1CYP2C9HSD17B10TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-11274093-B2 | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2022-03-15 | — | — | US | disclosed |
| US-11059819-B2 | Fused hetero-hetero bicyclic compounds and methods of use thereof | JANSSEN BIOTECH, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200385364-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2020-12-10 | — | — | US | disclosed |
| US-20190345158-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-11-14 | — | — | US | disclosed |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | ALOX15 4495/4885ALDH1A1 4072/4885CYP2C9 3242/4885 |
| US-11274093-B2 | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof | KRAS, NRAS, HRAS | ALOX15 4167/4885ALDH1A1 2199/4885CYP2C9 3482/4885 |
| US-11059819-B2 | Fused hetero-hetero bicyclic compounds and methods of use thereof | KRAS, NRAS, HRAS | ALOX15 4120/4885ALDH1A1 4653/4885CYP2C9 2581/4885 |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALOX15 4525/4885ALDH1A1 1402/4885CYP2C9 3016/4885 |
| US-20190345158-A1 | FUSED HETERO-HETERO BICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALOX15 4120/4885ALDH1A1 4653/4885CYP2C9 2581/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALOX15 4579/4885ALDH1A1 4303/4885CYP2C9 3239/4885 |
| US-20200385364-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALOX15 4632/4885ALDH1A1 1468/4885CYP2C9 2890/4885 |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | KRAS, NRAS, HRAS | ALOX15 4640/4885ALDH1A1 1729/4885CYP2C9 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.